Liquidia Reports Strong 2025 Financial Performance with YUTREPIA Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy LQDA?
Source: Newsfilter
- Sales Growth: In 2025, YUTREPIA® achieved net product sales of $148.3 million, with fourth-quarter sales reaching $90.1 million, indicating strong market demand and product acceptance, thereby solidifying Liquidia's position in the specialty drug market.
- Profitability Improvement: The company recorded a net income of $14.6 million in the fourth quarter of 2025, marking its second consecutive profitable quarter, demonstrating rapid financial stability post-launch and enhancing its capacity for future investments and expansions.
- Strong Cash Position: As of December 31, 2025, Liquidia's cash and cash equivalents totaled $190.7 million, an increase of $33.2 million from the third quarter, ensuring financial flexibility for future R&D and marketing initiatives.
- Prescription Growth: Since its launch in June 2025, YUTREPIA has received over 3,600 unique prescriptions and treated more than 2,900 patients, with a prescription-to-start conversion rate maintained above 85%, reflecting high recognition and trust from both physicians and patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.280
Low
31.00
Averages
47.50
High
67.00
Current: 42.280
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Corporation Emerges as Top Stock Pick with Significant Upside
- Holding Changes: Farallon Capital first held 1.8 million shares of Liquidia in Q2 2020, reestablishing a position of 2 million shares in Q1 2024, and increasing to 8.6 million shares by Q4 2025, reflecting sustained confidence and investment potential in the company.
- Market Performance: Liquidia reported $90.1 million in product sales for Q4 2025, a 74% increase from Q3, indicating rapid adoption of its product YUTREPIA in the pulmonary hypertension market, further solidifying its market position.
- Industry Outlook: Viewed as a disruptive force in the pulmonary hypertension market, Liquidia faces litigation from United Therapeutics, yet its transition to profitability and expansion of its sales force targeting over 860 active prescribers signal strong future growth potential.
- Strategic Goals: CEO Roger Jeffs confirmed a clear path for Liquidia to achieve $1 billion in revenue by 2027, showcasing the company's robust growth prospects and investment appeal in the biopharmaceutical sector.
See More
Liquidia CEO Indirectly Sells 53,300 Shares
- Indirect Share Sale: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating the company's agility in capital management.
- Updated Holdings: Following this transaction, Liquidia's direct and indirect holdings stand at 1,137,599 and 1,441,934 shares respectively, reflecting management's continued confidence in the company's future direction.
- Strong Yutrepia Sales: Liquidia's dry inhalable treprostinil drug, Yutrepia, achieved an annualized sales figure of $360.4 million in Q4 2025, demonstrating market acceptance that exceeded expectations and enhancing the company's profitability.
- Future Development Potential: Liquidia is developing an extended-release formulation of treprostinil, L606, which is currently in pivotal studies; if successful, this could further solidify its market position in pulmonary hypertension treatments.
See More
Liquidia CEO Indirectly Sells 53,300 Shares, Raising $2.14 Million
- Transaction Overview: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating a continued preference for liquidity management through indirect vehicles.
- Holding Change Analysis: The 53,300 shares sold represent 2.02% of total holdings and 3.56% of indirect holdings, reflecting a measured reduction while maintaining a substantial direct ownership value of around $47.10 million.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, classifying it as a routine, pre-scheduled liquidity event rather than a discretionary market-timed action, which reflects management's confidence in the company's future.
- Product Performance Highlights: Liquidia's Yutrepia achieved annualized sales of $360.4 million in Q4 2025, with a net income of $14.6 million, showcasing strong market performance in the pulmonary arterial hypertension treatment space, further bolstering investor confidence.
See More
Liquidia CFO Sells Significant Shares
- Executive Sell-off: On April 9, 2026, Liquidia's CFO and COO, Michael Kaseta, sold 133,789 shares of the company, totaling $5,383,38, which may raise concerns about the company's future outlook among investors.
- Market Reaction: Such executive sell-offs are often perceived as negative signals for stock performance, potentially leading to a decline in investor confidence in Liquidia and affecting its stock price.
- Shareholding Structure Change: Kaseta's sell-off could alter Liquidia's shareholder structure, especially if executive ownership is significant, raising questions about corporate governance and management stability.
- Future Outlook: While the sell-off may cause market fluctuations, investors should continue to monitor Liquidia's fundamentals and future strategic direction to assess its long-term investment value.
See More
Liquidia CEO Sells Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 25,000 shares on April 9, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often interpreted as a lack of confidence in the company's performance.
- Market Reaction: This sell-off could lead to a decline in investor trust in Liquidia, potentially impacting its stock price, especially given the heightened sensitivity of investors to executive actions in the current market environment.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly as changes in executive shareholding can influence their strategic impact on the company.
- Uncertain Future Outlook: While the sell-off itself does not necessarily indicate a deterioration in the company's fundamentals, the market may adopt a cautious stance towards Liquidia's future development, especially in the context of intense competition in the biopharmaceutical industry.
See More
Form 144: Liquidia (LQDA.US) Executive Plans to Sell $5.11 Million in Common Shares
Share Sale Announcement: Michael Kaseta intends to sell 133,790 shares of Liquidia (LQDA.US) on April 9, with a total market value of approximately $5.11 million.
Reduction in Holdings: Since January 12, 2026, Michael Kaseta has reduced his shareholding in Liquidia by 38,097 shares, valued at around $1.42 million.
See More
Liquidia Corporation Emerges as Top Stock Pick with Significant Upside
- Holding Changes: Farallon Capital first held 1.8 million shares of Liquidia in Q2 2020, reestablishing a position of 2 million shares in Q1 2024, and increasing to 8.6 million shares by Q4 2025, reflecting sustained confidence and investment potential in the company.
- Market Performance: Liquidia reported $90.1 million in product sales for Q4 2025, a 74% increase from Q3, indicating rapid adoption of its product YUTREPIA in the pulmonary hypertension market, further solidifying its market position.
- Industry Outlook: Viewed as a disruptive force in the pulmonary hypertension market, Liquidia faces litigation from United Therapeutics, yet its transition to profitability and expansion of its sales force targeting over 860 active prescribers signal strong future growth potential.
- Strategic Goals: CEO Roger Jeffs confirmed a clear path for Liquidia to achieve $1 billion in revenue by 2027, showcasing the company's robust growth prospects and investment appeal in the biopharmaceutical sector.
See More
Liquidia CEO Indirectly Sells 53,300 Shares
- Indirect Share Sale: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating the company's agility in capital management.
- Updated Holdings: Following this transaction, Liquidia's direct and indirect holdings stand at 1,137,599 and 1,441,934 shares respectively, reflecting management's continued confidence in the company's future direction.
- Strong Yutrepia Sales: Liquidia's dry inhalable treprostinil drug, Yutrepia, achieved an annualized sales figure of $360.4 million in Q4 2025, demonstrating market acceptance that exceeded expectations and enhancing the company's profitability.
- Future Development Potential: Liquidia is developing an extended-release formulation of treprostinil, L606, which is currently in pivotal studies; if successful, this could further solidify its market position in pulmonary hypertension treatments.
See More
Liquidia CEO Indirectly Sells 53,300 Shares, Raising $2.14 Million
- Transaction Overview: Liquidia's CEO Roger Jeffs indirectly sold 53,300 shares through Serendipity BioPharma LLC, generating approximately $2.14 million, indicating a continued preference for liquidity management through indirect vehicles.
- Holding Change Analysis: The 53,300 shares sold represent 2.02% of total holdings and 3.56% of indirect holdings, reflecting a measured reduction while maintaining a substantial direct ownership value of around $47.10 million.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, classifying it as a routine, pre-scheduled liquidity event rather than a discretionary market-timed action, which reflects management's confidence in the company's future.
- Product Performance Highlights: Liquidia's Yutrepia achieved annualized sales of $360.4 million in Q4 2025, with a net income of $14.6 million, showcasing strong market performance in the pulmonary arterial hypertension treatment space, further bolstering investor confidence.
See More
Liquidia CFO Sells Significant Shares
- Executive Sell-off: On April 9, 2026, Liquidia's CFO and COO, Michael Kaseta, sold 133,789 shares of the company, totaling $5,383,38, which may raise concerns about the company's future outlook among investors.
- Market Reaction: Such executive sell-offs are often perceived as negative signals for stock performance, potentially leading to a decline in investor confidence in Liquidia and affecting its stock price.
- Shareholding Structure Change: Kaseta's sell-off could alter Liquidia's shareholder structure, especially if executive ownership is significant, raising questions about corporate governance and management stability.
- Future Outlook: While the sell-off may cause market fluctuations, investors should continue to monitor Liquidia's fundamentals and future strategic direction to assess its long-term investment value.
See More
Liquidia CEO Sells Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 25,000 shares on April 9, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often interpreted as a lack of confidence in the company's performance.
- Market Reaction: This sell-off could lead to a decline in investor trust in Liquidia, potentially impacting its stock price, especially given the heightened sensitivity of investors to executive actions in the current market environment.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly as changes in executive shareholding can influence their strategic impact on the company.
- Uncertain Future Outlook: While the sell-off itself does not necessarily indicate a deterioration in the company's fundamentals, the market may adopt a cautious stance towards Liquidia's future development, especially in the context of intense competition in the biopharmaceutical industry.
See More
Form 144: Liquidia (LQDA.US) Executive Plans to Sell $5.11 Million in Common Shares
Share Sale Announcement: Michael Kaseta intends to sell 133,790 shares of Liquidia (LQDA.US) on April 9, with a total market value of approximately $5.11 million.
Reduction in Holdings: Since January 12, 2026, Michael Kaseta has reduced his shareholding in Liquidia by 38,097 shares, valued at around $1.42 million.
See More
